-
Purposehuman PDL-1 coding sequence subcloned into pMP71 retroviral plasmid
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 118631 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepMP71
- Backbone size w/o insert (bp) 5500
- Total vector size (bp) 6516
-
Modifications to backboneGateway compatible (see Wälchli et al. 2011, PlosONE)
-
Vector typeMammalian Expression
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)NEB Stable
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert namehPDL-1
-
Alt nameProgrammed cell death 1 ligand 1
-
Alt namePDCD1 ligand 1
-
Alt nameCD274
-
SpeciesH. sapiens (human)
-
Insert Size (bp)872
-
GenBank IDNM_001267706.1 NM_014143.3
-
Entrez GeneCD274 (a.k.a. B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1)
- Promoter LTR
Cloning Information
- Cloning method Gateway Cloning
- 5′ sequencing primer T7
- 3′ sequencing primer M13rev (Common Sequencing Primers)
Resource Information
-
A portion of this plasmid was derived from a plasmid made byGene was order as a synthetic fragment corresponding to the original coding sequence (isoform 1)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pMP71-hPDL-1 was a gift from Sébastien Walchli (Addgene plasmid # 118631 ; http://n2t.net/addgene:118631 ; RRID:Addgene_118631) -
For your References section:
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma. Josefsson SE, Beiske K, Blaker YN, Forsund MS, Holte H, Ostenstad B, Kimby E, Koksal H, Walchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH. Cancer Immunol Res. 2019 Mar;7(3):355-362. doi: 10.1158/2326-6066.CIR-18-0351. Epub 2019 Jan 18. 10.1158/2326-6066.CIR-18-0351 PubMed 30659053